RxDoctor Payments Data

Patricia Melville

Neurology · East Setauket, NYNPI 1033440896

Payments from drug & device makers

$337,338in general payments, 2019–2025

Across 562 payments — averaging $600.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$87K
  • Genentech USA, Inc.$70K
  • TG Therapeutics, Inc.$63K
  • EMD Serono, Inc.$40K
  • Biogen$30K
  • E.r. Squibb & Sons, L.L.C.$19K
  • plus $30K from 14 others

What the payments were for

  • Consulting fees$41,13812%
  • Speaking & faculty fees$239,32271%
  • Travel & lodging$38,91812%
  • Food & beverage$17,9615%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$337,338 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$62,874
Medicare patients
223
Services billed
727

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab18$680,356
VumerityDiroximel Fumarate21$253,334
MayzentSiponimod23$220,488
Teriflunomide43$215,035
RebifInterferon Beta-1a/Albumin14$147,275
LamictalLamotrigine92$145,368
Avonex (4 Pack)Interferon Beta-1a12$139,726
ZonegranZonisamide43$124,420
BriviactBrivaracetam65$108,126
Dimethyl Fumarate17$106,516
XcopriCenobamate72$104,312
Dalfampridine ErDalfampridine44$91,597
Avonex Pen (4 Pack)Interferon Beta-1a11$86,207
EpidiolexCannabidiol (Cbd)25$75,506
Nurtec OdtRimegepant Sulfate55$74,291

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity, Avonex (4 Pack)$29,969$393,06033 claims
NovartisMayzent$6,550$220,48823 claims
EMD Serono, Inc.Rebif$39,533$147,27514 claims
AbbVieQulipta, Ubrelvy$346$95,83282 claims
PfizerNurtec Odt, Dilantin$24$78,22967 claims
Lundbeck LLCOnfi$62$27,81111 claims
Neurelis, Inc.Valtoco$537$9,07813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in East Setauket

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →